Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days

References

• Bartlett JG, Breiman RF, Mandell LA, File Jr. TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811–38
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820–37
   Google Scholar
• Gant V, Parton S. Community-acquired pneumonia. Curr Opin Pulm Med 2000;6:226–33
   PubMedGoogle Scholar
• Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513–28
   Google Scholar
• Marston BJ, Plouffe JF, File Jr. TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997;157:1709–18
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–54
   Google Scholar
• Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med 1985;78(Suppl 6B):45–51
   Google Scholar
• Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, epidemiology, and impact. Am J Med 1985;78:32–7
   PubMed Web of Science ®Google Scholar
• Spiritus EM, Chang RJ, Zhang JX, et al. Cost savings of clarithromycin compared with erythromycin or cefaclor in the treatment of lower respiratory tract infection: results of a randomized, multicenter study. Am J Manag Care 1998;4(Suppl):S562–S570
   Google Scholar
• Birnbaum HG, Morley M, Greenberg PE, Colice GL. Economic burden of respiratory tract infections in an employed population. Chest 2002;122:603–11
   PubMed Web of Science ®Google Scholar
• Mandell LA. Community-acquired pneumonia. Etiology, epidemiology, and treatment. Chest 1995;108(Suppl 2):S35–S42
   Google Scholar
• Bernstein JM. Treatment of community-acquired pneumonia – IDSA guidelines. Chest 1999;115(Suppl):9S–13S
   Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Infectious Diseases Society of America. Clin Infect Dis 2003;37:1405–33
   Google Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399–408
   PubMed Web of Science ®Google Scholar
• Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31:383–421
   Google Scholar
• Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. J Infect 2002;44(Suppl A):3–10
   Google Scholar
• Barman Balfour JA, Figgitt DP. Telithromycin. Drugs 2001;61:815–31
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Walters M, Noreddin A, et al. The ketolides: a critical review. Drugs 2002;62:1771–804
   PubMed Web of Science ®Google Scholar
• Aventis. Ketek (telithromycin). Briefing document for the FDA anti-infective drug products advisory committee meeting (January 2003). Available from: http://www.fda.gov/ohrms/ dockets/ac/03/briefing/3919B1_01_Aventis-KETEK.pdf [Last accessed 19 December 2003]
   Google Scholar
• Dunbar LM, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48–62
   Google Scholar
• Tellier G, Isakov T, Petermann W, Patel M, Lavin B. Efficacy and safety of telithromycin for 5 or 7 days vs clarithromycin for 10 days in the treatment of patients with community-acquired pneumonia [Abstract L373]. In: Abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington (DC): American Society for Microbiology; 2002
   Google Scholar
• Niederman MS, Chang JR, Stewart J, Nusrat N, Nieman RB. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Curr Med Res Opin 2004;20(5):749–56
   Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med 1997;336:243–50
   PubMed Web of Science ®Google Scholar
• American Hospital Association (AHA) Hospital Statistics. Data derived from responses to the 1999 AHA Annual Survey. In: Hospital statistics, 2001 ed. Chicago: Health Forum LLC, an affiliate of the American Hospital Association; 2001
   Google Scholar
• Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096–121
   Web of Science ®Google Scholar
• Davey PG, Malek MM, Parker SE. Pharmacoeconomics of antibacterial treatment. Pharmacoeconomics 1992;1:409–37
   PubMedGoogle Scholar
• Felmingham D, Grüneberg RN, The Alexander Project Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45: 191–203
   Google Scholar
• Chang JR, Stewart J, Cadilhac M, Nieman RB. Telithromycin (TEL) results in fewer hospitalizations than amoxicillin–clavulanate (AMC) in the outpatient treatment of acute exacerbations of chronic bronchitis (AECB). Value Health 2003;6:250–51
   Web of Science ®Google Scholar
• Mandell L, Chang J, Oster G, Stewart J, Pluim J, Liss M, Nieman R. Comparison of healthcare utilization in patients with acute exacerbations of chronic bronchitis (AECB) receiving telithromycin (TEL) versus clarithromycin (CLA) in a randomized, double-blind, multicenter clinical trial [Abstract L1595]. In: Abstracts of the 43rd interscience conference on antimicrobial agents and Chemotherapy. Washington (DC): American Society for Microbiology; 2003
   Google Scholar
• Nicolau DP. Pharmacodynamic rationale for short-duration antibacterial therapy. J Infect 2002;44(Suppl A):17–23
   Google Scholar
• Odenholt L, Löwdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001;45:23–9
   PubMed Web of Science ®Google Scholar
• Norrby SR, Chang J, Stewart JA, Brumpt I, Conway DP. Relief of symptoms in patients with group A beta-hemolytic streptococcus tonsillopharyngitis: comparison between telithromycin and penicillin V. Scand J Infect Dis 2003;35:223–5
   Google Scholar